Fabry disease: raising awareness of the disease among physicians.
Fabry disease is an X-linked inherited lysosomal disorder due to dysfunctions of the lysosomal enzyme alpha-galactosidase A, causing insufficient breakdown of glycolipids, which are stored in the eyes, kidneys, autonomic nervous system, skin, vessels and cardiovascular system. Manifestations of Fabry disease include progressive renal and cardiac insufficiency, neuropathic pain, stroke and cerebral disease, skin and gastrointestinal symptoms. Clinical onset usually occurs in childhood, but many severe patients are diagnosed in adulthood. Females may be severely affected as males and both may die prematurely due to stroke, heart disease and renal failure. Enzyme replacement therapy can stabilize or reduce the progression of the disease. There is a need to improve the knowledge of Fabry disease, as an early therapy may prevent complications of the disease. This brief overview aims to raise awareness of the signs and symptoms of Fabry disease and to summarize the effects of treatments.
Department of Medicine, Endocrinology, Metabolism and Geriatrics, University of Modena and Reggio Emilia, NOSE U.O. Medicina ad indirizzo metabolico-nutrizionistico, Via Giardini 1355, 41126, Modena, MO, Italy. carubbi@unimore.it
Francesca
F
Carubbi
Lisa
L
Bonilauri
D003937:Diagnosis, Differential; D056947:Enzyme Replacement Therapy / Q000379:methods*; D000795:Fabry Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics; D006801:Humans